Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 GeneAzam Ghafoor, Raffit Hassan, Idrees Mian et al.|JTO Clinical and Research Reports|2021Cited by 57
Treatment of Pleural Mesothelioma: ASCO Guideline UpdateHedy L. Kindler, Raffit Hassan, Nofisat Ismaila et al.|Journal of Clinical Oncology|2025Cited by 55
Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes.Raffit Hassan, Azam Ghafoor, Cathy Wagner et al.|Journal of Clinical Oncology|2020Cited by 22
Multiple Onychopapillomas and BAP1 Tumor Predisposition SyndromeAlexandra Lebensohn, Edward W. Cowen, Azam Ghafoor et al.|JAMA Dermatology|2024Cited by 17
Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 MutationsZishuo I. Hu, Azam Ghafoor, Markku Miettinen et al.|Journal of Thoracic Oncology|2021Cited by 7